<!–*/ */ /*–>*/ Microsoft MSFT and Adaptive Biotechnologies ADPT recently extended partnership in a bid to aid public health officials and researchers to access and track data pertaining to COVID-19 patient immune responses.The dataset is aimed at enabling health care practitioners to develop diagnostic blood test through which virus can detected accurately despite people being asymptomatic. Moreover, the dataset can be leveraged to analyze and enhance the order of treatment for newly diagnosed COVID-19 patients.The open source dataset will be deployed on Microsoft’s cloud computing platform, Azure. Microsoft’s robust Azure Artificial Intelligence (AI) and machine learning (ML) capabilities will complement Adaptive’s strength in “immunosequencing” technology.Increasing adoption of Azure to support healthcare workloads provide the cloud platform with immense exposure in the domain, which is a positive. Robust adoption of the company’s offerings is instilling confidence in the stock.Notably, shares of the company have returned 16.7% in the past year, compared with the industry’s rally of 1.7%.Microsoft & Healthcare Players Team UpThe researchers and public-he...